Skip to main content

Scienture Holdings, Inc.

For the period ended Dec 31, 2024. Filed Mar 26, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 26, 2025

SCNX$3.20+2.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

CONSOLIDATED BALANCE SHEETS

December 31, 2024 and 2023

December 31,
20242023
ASSETS
Current assets:
Cash$308,096$314
Accounts receivable, net11,106-
Inventory-968
Prepaid expenses4,56050,724
Notes receivable - related party1,300,0001,300,000
Other receivables4,138,7701,224,702
Deferred offering costs534,800-
Current assets of discontinued operations8,145176,355
Total current assets6,305,4772,753,063
Property, plant and equipment, net17,5007,500
Deposits22,03910,531
Intangible assets, net76,400,000-
Goodwill21,372,960-
Operating lease right-of-use assets201,433191,216
Deferred tax asset534,396-
Noncurrent assets of discontinued operations-9,570,603
Total assets$104,853,805$12,532,913
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable$2,898,683$1,463,014
Accrued liabilities1,313,731160,214
Other current liabilities5,44167,831
Loan payable, related party415,000-
Convertible note, net of debt discount - current portion2,285,423
Contingent funding liabilities-1,246,346
Operating lease liability - current63,33432,595
Warrant liability919,935736,953
Current liabilities of discontinued operations5,3467,849,402
Total current liabilities7,906,89311,556,355
Convertible notes, net of debt discount612,275-
Derivative liability2,296,834-
Operating lease liability - net of current portion156,469176,909
Development agreement liability1,285,000-
Deferred tax liability13,524,213
Noncurrent liabilities of discontinued operations-257,296
Total liabilities25,781,68411,990,560
Commitments and contingencies (Note 15)--
Stockholders’ equity (deficit):
Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of December 31, 2024 and 2023, all respectively--
Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both December 31, 2024 and 2023--
Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 and 290 shares issued and outstanding as of December 31, 2024 and 2023, respectively--
Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively--
Common stock, $0.00001 par value; 100,000,000 shares authorized; 8,750,582 and 905,008 shares issued and outstanding as of December 31, 2024 and 2023, respectively879
Additional paid-in capital118,111,00733,788,284
Accumulated deficit(39,038,973)(33,245,940)
Total stockholders’ equity79,072,121542,353
Total liabilities and stockholders’ equity$104,853,805$12,532,913
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.